IL11 Knockout SK-OV-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the IL11 gene has been disrupted in SK-OV-3 human ovarian adenocarcinoma cells. This loss-of-function model is produced by CRISPR/Cas9-mediated gene disruption, generating a mixed pool of cells with IL11 inactivation. The polyclonal format avoids clonal bias and offers a robust population-level knockout for studying IL-11-dependent biology.
SK-OV-3 is an epithelial cell line derived from the ascitic fluid of an ovarian adenocarcinoma patient. It serves as a well-characterized model of high-grade serous ovarian carcinoma, commonly used to investigate tumor proliferation, drug response, and metastasis. The cell line carries a TP53 mutation and exhibits adherent growth, making it suitable for both in vitro assays and in vivo xenograft studies.
IL-11 is a pleiotropic cytokine that initiates signaling by binding to its specific receptor IL-11R?? and the co-receptor gp130. This interaction activates JAK1 and JAK2, leading to STAT3 phosphorylation and nuclear translocation. STAT3 drives transcription of targets such as cyclin D1, Bcl-2, and survivin, promoting proliferation and survival. IL-11 also stimulates MAPK/ERK and PI3K/AKT cascades. Upstream regulators include TGF-??, IL-1, TNF-??, and AP-1. Negative regulation is provided by SOCS3. IL-11 signaling enhances cell migration and invasion via upregulation of MMP2 and MMP9.
In ovarian cancer, autocrine and paracrine IL-11 loops contribute to tumor growth, chemoresistance, and metastasis. Removing IL-11 from SK-OV-3 cells allows direct assessment of its role in JAK/STAT3-mediated oncogenic processes, including evasion of apoptosis and matrix degradation. This knockout system provides a defined background to distinguish tumor-intrinsic IL-11 effects from microenvironment-derived signals, and to explore its interplay with other oncogenic drivers prevalent in ovarian adenocarcinoma.
Applications include detailed signaling studies via western blotting and phospho-STAT3 analysis, transcriptional profiling by RT-qPCR, and functional assays such as CellTiter-Glo viability, Transwell migration, and Matrigel invasion. The model is also valuable for drug sensitivity testing and high-content screening to identify compounds targeting the IL-11 pathway. For more information and ordering, please contact Ascent Research.
